Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 154
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
1.
Allergy ; 71(7): 1001-9, 2016 07.
Article in English | MEDLINE | ID: mdl-26841365

ABSTRACT

BACKGROUND: In our prior randomized trial on preventing influenza, asthma attacks as a secondary outcome occurred less often in the vitamin D group than in the placebo group. We aimed to clarify whether low-dose, short-term vitamin D supplementation, in addition to standard treatments, improves control of childhood asthma. METHODS: We conducted a randomized, double-blind, placebo-controlled trial comparing vitamin D3 supplements (800 IU/day) with placebo for 2 months in schoolchildren with asthma. The primary outcomes were frequency and severity of asthma judging from changes in asthma control levels defined by the Global Initiative for Asthma (GINA) by collaborating doctors at 2 and 6 months. RESULTS: Japanese schoolchildren with asthma (n = 89) were randomly assigned to receive vitamin D (n = 54) or placebo (n = 35). At 2 months, GINA asthma control was significantly more improved in the vitamin D group compared with the placebo group (P = 0.015). Childhood asthma control test (CACT) scores, a secondary outcome, were also significantly (P = 0.004) improved in the vitamin D group compared with the placebo group at 2 months, and differences remained significant (P = 0.012) at 6 months. The proportion of patients with a peak expiratory flow rate <80% predicted was significantly less in the vitamin D group (8/54: 15%) than in the placebo group (12/35: 34%) at 6 months (P = 0.032). CONCLUSIONS: Low-dose, short-term vitamin D supplementation in addition to standard treatment may improve levels of asthma control in schoolchildren.


Subject(s)
Asthma/drug therapy , Dietary Supplements , Vitamin D/administration & dosage , Allergens/immunology , Animals , Asthma/diagnosis , Asthma/etiology , Asthma/prevention & control , Biomarkers , Child , Comorbidity , Disease Progression , Female , Humans , Immunoglobulin E/immunology , Male , Respiratory Function Tests , Treatment Outcome , Vitamin D/adverse effects
2.
Mol Cell Biol ; 20(9): 3266-73, 2000 May.
Article in English | MEDLINE | ID: mdl-10757810

ABSTRACT

Transforming growth factor beta (TGF-beta) plays important roles in the regulation of proliferation, differentiation, apoptosis, and carcinogenesis. To identify genes responsible for maintaining the phenotype induced by TGF-beta, we performed a retrovirus-mediated gene trap screening designed to isolate TGF-beta-responsive genes in human lung carcinoma cell line A549. After screening 249 trap lines, 21 were found to express the reporter beta-galactosidase gene in a TGF-beta-responsive manner. Interestingly, in large proportions of these trap lines, the reporter gene was responsive also to phorbol ester and was suppressed by gamma interferon. Fragments of all these trapped genes were recovered by 5'- and 3'-rapid amplification of cDNA ends (RACE), and in 15 out of 21 cases (71%), the TGF-beta responsiveness of the endogenous genes was confirmed by RNA blot hybridization. In at least five cases, the TGF-beta-induced upregulation was found to be cycloheximide resistant, suggesting the roles of the genes in the TGF-beta-induced primary responses. Sequence analyses revealed that 43% (9 of 21) of the trapped genes were novel and that the remainder included genes previously reported to be upregulated by TGF-beta, such as epidermal growth factor receptor and beta1 integrin, documenting the validity of this approach. Other known genes include the ones encoding the proteins associated with cell proliferation (ribosomal proteins S15a, hNRP/NAP-1, and lipocortin II), focal adhesions (paxillin), and transcriptional regulation (thyroid hormone receptor activator molecule 1 [TRAM-1]).


Subject(s)
Genetic Techniques , Transforming Growth Factor beta/genetics , Blotting, Northern , DNA, Complementary/metabolism , Galactosides/metabolism , Genes, Reporter , Humans , Indoles/metabolism , RNA, Messenger/metabolism , Retroviridae/genetics , Sequence Analysis, DNA , Transforming Growth Factor beta/metabolism , Tumor Cells, Cultured , Up-Regulation , beta-Galactosidase/metabolism
3.
Cancer Res ; 54(22): 5821-3, 1994 Nov 15.
Article in English | MEDLINE | ID: mdl-7954408

ABSTRACT

A highly efficient method to obtain a subtracted genomic DNA library using 1 microgram of target DNA was developed by modification of the previously reported in-gel competitive reassociation procedure. The modified method was based on polymerase chain reaction amplification after selective purification of a target-target reassociated molecule of subtracted DNA fragments to increase cloning efficiency. For a model experimental system, the subtracted DNA library was constructed after two cycles of subtractive reassociation between cervical cancer DNA fragments containing human papilloma virus DNA and the 100-fold excess of dephosphorylated normal tissue DNA fragments which were size-fractionated in agarose gel. Colony hybridization using human papilloma virus DNA as a probe revealed that a more than 500-fold enrichment of human papilloma virus DNA sequences in the subtracted DNA library could easily be obtained. This simple and efficient method will enable us to isolate an unknown foreign DNA fragment and an unknown amplified DNA fragment which might be present in cancer.


Subject(s)
Cloning, Molecular/methods , DNA, Neoplasm/isolation & purification , DNA, Viral/isolation & purification , Genomic Library , Nucleic Acid Amplification Techniques , Base Sequence , Female , Humans , Molecular Sequence Data , Papillomaviridae/genetics , Placenta/chemistry , Polymerase Chain Reaction/methods , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/virology
4.
Cancer Res ; 46(6): 3067-74, 1986 Jun.
Article in English | MEDLINE | ID: mdl-3486043

ABSTRACT

Four monocytoid cell lines, JOSK-I, -S, -M, and -K, were newly established successfully from peripheral blood of two cases of acute monocytic leukemia and one case each of acute myelomonocytic leukemia and chronic myelogenous leukemia in myelomonocytic blast crisis. In order to establish permanent cell lines, cultures of leukemic blasts were initiated in 96-well microtiter plates. Each cell line grew in a suspension culture with a doubling time of 24-32 h and has been serially maintained for over 20 mo. Each line had immature monocytic properties as judged from the results of cytological, immunochemical, and functional analyses. The cells showed a positive reaction for alpha-naphthyl butyrate esterase which was completely inhibited by sodium fluoride and exhibited immature monocytic features on electron microscopic observation. They also had surface markers specific for the monocyte-macrophage lineage. Chromosome analyses showed that each line had a variety of marker chromosomes; furthermore, these established lines exhibited high potentialities involving morphological and functional differentiation into more mature monocytic cells when induced by several chemical inducers. We also found that two of the established cell lines produced much interleukin 1 activity without any stimuli. These new lines might be valuable for studying the regulation of monocyte-macrophage differentiation and host defense mechanisms.


Subject(s)
Cell Differentiation , Interleukin-1/biosynthesis , Leukemia, Myeloid/pathology , Macrophages/pathology , Monocytes/pathology , Aged , Cell Differentiation/drug effects , Cell Line , Dimethyl Sulfoxide/pharmacology , Female , Humans , Karyotyping , Leukemia, Myeloid/genetics , Leukemia, Myeloid/metabolism , Male , Middle Aged , Phagocytosis , Philadelphia Chromosome , Tetradecanoylphorbol Acetate/pharmacology , Tretinoin/pharmacology
5.
Cancer Res ; 54(2): 377-9, 1994 Jan 15.
Article in English | MEDLINE | ID: mdl-8275473

ABSTRACT

To identify genes activated by chromosome translocation t(11;14)(q13;q32), mRNA levels of five genes (cyclin D1, EXP1, MB38, HST1, and INT2) at chromosome 11q13 were investigated. The cyclin D1 mRNA increased in BCL-1-rearranged B-cell tumor cell lines SP-49, NOP-2, FLAM-76, KMS-12-PE, and KMS-12-BM cells, while it was not detected in cell lines without the translocation, Raji, U266, and HEL cells. A significant amount of the MB38 mRNA was detected irrelevantly to the translocation in all of these cell lines. The mRNAs of EXP1, HST1, and INT2 were undetectable in these cells. The results suggested that the translocation activates cyclin D1 alone, while the mRNA levels of the other four genes are regulated independently of the translocation.


Subject(s)
Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 14 , Cyclins/genetics , Lymphoma, B-Cell/genetics , Multiple Myeloma/genetics , Oncogene Proteins/genetics , RNA, Messenger/analysis , RNA, Neoplasm/analysis , Translocation, Genetic , Blotting, Northern , Cyclin D1 , Humans
6.
Cancer Res ; 57(16): 3548-53, 1997 Aug 15.
Article in English | MEDLINE | ID: mdl-9270027

ABSTRACT

An improved cDNA selection method was established to isolate expressed genes efficiently from an amplified chromosome region in human cancer. Biotinylated yeast artificial chromosome DNA containing c-ERBB-2 was hybridized in solution with PCR-amplifiable cDNAs of an esophageal cancer cell line bearing the c-ERBB-2 amplification. After capturing the hybrids on avidin-coated magnetic beads, the cDNAs were amplified by PCR. Four new genes (A39, C51, CAB1, and GRB-7) coamplified with c-ERBB-2 were isolated from the enriched cDNA library. CAB1, GRB-7, and c-ERBB-2 were overexpressed in gastric and esophageal cancer cells in correspondence with the amplification. The deduced amino acid sequence of the CAB1 gene had significant homology to the recently discovered steroidogenic acute regulatory protein, StAR, which plays an essential role in cholesterol transport to mitochondria. It was established that multiple overexpressed genes are frequently present in a single amplicon.


Subject(s)
Carrier Proteins/genetics , Cholesterol/metabolism , Esophageal Neoplasms/genetics , Genes, erbB-2/genetics , Membrane Proteins , Stomach Neoplasms/genetics , Amino Acid Sequence , Base Sequence , Carrier Proteins/metabolism , Chromosome Mapping , DNA, Complementary/genetics , Esophageal Neoplasms/metabolism , GRB7 Adaptor Protein , Humans , Molecular Sequence Data , Proteins/genetics , Proteins/metabolism , Sequence Analysis, DNA , Stomach Neoplasms/metabolism , Tumor Cells, Cultured
7.
Oncogene ; 12(10): 2137-46, 1996 May 16.
Article in English | MEDLINE | ID: mdl-8668339

ABSTRACT

A cDNA (termed CT124) encoding a carboxyl-terminal fragment of the human homeobox protein MSX-2 was found to induce flat reversion when expressed in v-Ki-ras-transformed NIH3T3 cells. Although the expression of endogenous MSX-2 gene is low in most of the normal adult tissues examined, it is frequently activated in carcinoma-derived cell lines. Likewise, the gene is inactive in NIH3T3 cells but is transcriptionally activated after transformation by v-Ki-ras oncogene, suggesting that the intact MSX-2 may play a positive, rather than suppressive, role in cell transformation. To test this possibility, we isolated a near full-length human MSX-2 cDNA and tested its activities in two cell systems, i.e. fibroblast and myoblast. In NIH3T3 fibroblasts, although the gene by itself failed to confer a transformed phenotype, antisense MSX-2 cDNA as well as truncated CT124 cDNA interfered with the transforming activities of v-Ki-ras oncogene. In C2C12 myoblasts, MSX-2 was found to suppress MyoD gene expression, as do activated ras oncogenes, under certain culture conditions, and CT124 was found to inhibit the activities of both MSX-2 and ras in this system as well. Our findings not only suggest that CT124 may act as a dominant suppressor of MSX-2 but also raise the possibility that MSX-2 gene may be an important downstream target for the Ras signaling pathways.


Subject(s)
Cell Transformation, Neoplastic/genetics , DNA, Complementary/genetics , DNA, Complementary/isolation & purification , DNA-Binding Proteins/genetics , Genes, Tumor Suppressor , Genes, ras , 3T3 Cells/physiology , Amino Acid Sequence , Animals , Base Sequence , Chick Embryo , DNA Probes , DNA-Binding Proteins/physiology , Gene Expression Regulation, Neoplastic , Homeodomain Proteins , Mice , Molecular Sequence Data , Sequence Homology, Amino Acid , ras Proteins/genetics , ras Proteins/physiology
8.
Diabetes ; 37(9): 1168-72, 1988 Sep.
Article in English | MEDLINE | ID: mdl-3044883

ABSTRACT

1,2-Diacylglycerol has been proposed to be a secondary messenger; therefore, in this study we evaluated the amount of 1,2-diacylglycerol in heart tissue from streptozocin-induced diabetic rats and examined the effect of insulin treatment on 1,2-diacylglycerol content. Diabetic rats had lower body and ventricular weights and higher ratios of ventricular to body weight, all of which shifted toward normal values after 4 wk of untreated diabetes followed by 4 wk of insulin treatment. The contents of major phospholipids were significantly depressed in the diabetic rat hearts. In contrast, the triglyceride and cholesterol contents in the myocardium were increased by streptozocin injection and completely normalized by insulin treatment, and glucose levels returned to normal. The 1,2-diacylglycerol content in the myocardium was also significantly elevated in the diabetic rats compared with age-matched controls. Moreover, the 1,2-diacylglycerol content was significantly higher in rats with 4 wk of diabetes than in those with 8 wk of diabetes. Insulin treatment in the diabetic rats, however, did not produce any decrease in 1,2-diacylglycerol content. The results of this study suggest that the development of cardiomyopathy induced by streptozocin injection is associated with a high 1,2-diacylglycerol level, which may result in the activation of protein kinase C. Insulin is one of the agonists that generates 1,2-diacylglycerol in myocytes; however, the relationship between the sustained 1,2-diacylglycerol level and the normalization of diabetes by insulin administration is unclear.


Subject(s)
Diabetes Mellitus, Experimental/metabolism , Diglycerides/metabolism , Glycerides/metabolism , Myocardium/metabolism , Animals , Blood Glucose/metabolism , Cholesterol/metabolism , Diabetes Mellitus, Experimental/drug therapy , Heart/anatomy & histology , Insulin/blood , Insulin/therapeutic use , Male , Organ Size , Rats , Rats, Inbred Strains , Reference Values , Triglycerides/metabolism
9.
Diabetes ; 38(2): 231-6, 1989 Feb.
Article in English | MEDLINE | ID: mdl-2644143

ABSTRACT

The concentrations of acetylcholine (ACh) as a parasympathetic marker and norepinephrine (NE) as a sympathetic marker were investigated in the hearts of rats 2, 4, and 8 wk after the induction of diabetes by an injection of streptozocin (STZ; 65 mg/kg i.v.). ACh and NE were measured by high-performance liquid chromatography with electrochemical detection. Diabetic rats showed low body weight and heart weight at 2, 4, and 8 wk and higher heart-to-body weight ratio and bradycardia at 8 wk, almost all of which were normalized after insulin treatment. Myocardial ACh and NE concentrations in the diabetic rats at 2 and 4 wk were not significantly different from those in age-matched control rats. However, ACh and NE concentrations in the diabetic rats at 8 wk significantly increased compared with the control rats. Diabetic rats at 8 wk also had increased myocardial choline concentration and choline acetyltransferase activity and decreased acetylcholinesterase activity. Insulin treatment normalized all of these changes in the diabetic rats. Thus, in STZ-induced diabetes (STZ-D), the concentrations of both cholinergic and noradrenergic neurotransmitters in the myocardium increased. The results of this study confirm a previously reported increase in sympathetic activity to the heart and also indicate that there is an increase in the synthesis and a decrease in the metabolism of ACh in STZ-D and that adequate insulin treatment normalizes these changes.


Subject(s)
Acetylcholine/analysis , Cardiomyopathies/physiopathology , Diabetes Mellitus, Experimental/physiopathology , Myocardium/analysis , Norepinephrine/analysis , Parasympathetic Nervous System/physiopathology , Acetylcholinesterase/metabolism , Animals , Cardiomyopathies/etiology , Choline O-Acetyltransferase/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/metabolism , Heart/drug effects , Insulin/therapeutic use , Male , Myocardium/enzymology , Rats , Rats, Inbred Strains , Reference Values
10.
Leukemia ; 11 Suppl 3: 340-3, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9209384

ABSTRACT

A truncated MSX-2 homeoprotein was found to induce flat reversion when expressed in v-Ki-ras-transformed NIH3T3 cells. Although the expression of endogenous MSX-2 gene is low in most of the normal adult tissues examined, it is frequently activated in carcinoma-derived cell lines. Likewise, the gene is inactive in untransformed cells but is transcriptionally activated after transformation by v-Ki-ras oncogene, suggesting that the intact MSX-2 may play a positive, rather than suppressive, role in cell transformation. To test this possibility, we isolated a full-length human MSX-2 cDNA and tested its activities in two cell systems: fibroblast and myoblast. In NIH3T3 fibroblasts, although the gene by itself failed to confer a transformed phenotype, antisense MSX-2 cDNA as well as truncated MSX-2 cDNA interfered with the transforming activities of both v-Ki-ras and v-raf oncogene. In C2C12 myoblasts, MSX-2 was found to suppress MyoD gene expression, as do activated ras oncogenes, under certain culture conditions, and truncated MSX-2 cDNA was found to inhibit the activities of both MSX-2 and ras in this system as well. Our findings not only suggest that the truncated version MSX-2 may act as a dominant suppressor of intact MSX-2 but also raise the possibility that MSX-2 gene may be an important downstream target for the Ras signaling pathways.


Subject(s)
Cell Transformation, Neoplastic , DNA-Binding Proteins/metabolism , Genes, ras , Homeodomain Proteins/metabolism , 3T3 Cells , Animals , Cell Line , DNA-Binding Proteins/biosynthesis , Humans , Mice , Muscle, Skeletal , MyoD Protein/biosynthesis , Oncogene Protein p21(ras)/biosynthesis , Oncogene Proteins v-raf , Oncogenes , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , Retroviridae Proteins, Oncogenic/biosynthesis , Signal Transduction , Transcription, Genetic , Transfection , Tumor Cells, Cultured
11.
Clin Infect Dis ; 39 Suppl 1: S15-24, 2004 Jul 15.
Article in English | MEDLINE | ID: mdl-15250016

ABSTRACT

A multicenter open randomized trial was conducted to compare cefepime monotherapy with cefepime/amikacin combination (dual) therapy in treating febrile neutropenic patients with hematologic disorders. Among the 189 evaluable patients, 5.8% had microbiologically and 10.6% had clinically documented infections. Excellent response was seen in 32.6% and 45.7% of monotherapy and dual therapy recipients, respectively, at day 3 (P=.065). At day 3, patients with neutrophil counts of <500/ mu L receiving dual therapy had a better response than did those receiving monotherapy (45% vs. 27.6%; P=.024). The same was true for patients with leukemia. Adverse events were minimal, and early death was observed in 7 patients in the dual therapy group and 5 patients in the monotherapy group. Overall, cefepime monotherapy is as effective as dual therapy for the initial treatment of febrile neutropenic patients. Further study is warranted for patients with severe neutropenia and leukemia who may benefit from dual therapy.


Subject(s)
Amikacin/therapeutic use , Bacteremia/drug therapy , Cephalosporins/therapeutic use , Drug Therapy, Combination/therapeutic use , Hematologic Diseases/immunology , Immunocompromised Host , Neutropenia/drug therapy , Opportunistic Infections/drug therapy , Amikacin/administration & dosage , Antineoplastic Agents/adverse effects , Bacteremia/microbiology , Cefepime , Cephalosporins/administration & dosage , Female , Fever/complications , Hematologic Diseases/drug therapy , Humans , Japan , Leukemia/drug therapy , Leukemia/immunology , Male , Neutropenia/chemically induced , Neutropenia/complications
12.
FEBS Lett ; 466(1): 160-4, 2000 Jan 21.
Article in English | MEDLINE | ID: mdl-10648833

ABSTRACT

We have been isolating and analyzing NRK cell mutants, which fail to transform by epidermal growth factor (EGF) and transforming growth factor (TGF)-beta. One such mutant, R14, can respond to the growth inhibitory signal of TGF-beta to the same extent as parental NRK but fail to respond to the growth stimulatory signal of EGF. This mutant has a defect in EGF receptor (EGFR) expression. When R14 mutant expressed a high level of EGFR, however, EGF not only induced proliferation in this mutant but also induced transformation without the aid of TGF-beta. These findings suggest that the major role of TGF-beta in this transformation system should be to counteract the ligand-dependent down-regulation of EGFR, thereby sustaining high-level EGF-signaling.


Subject(s)
Cell Transformation, Neoplastic , Epidermal Growth Factor/physiology , Transforming Growth Factor beta/physiology , Animals , Base Sequence , Cell Line , Cell Transformation, Neoplastic/genetics , DNA Primers/genetics , Epidermal Growth Factor/pharmacology , ErbB Receptors/drug effects , ErbB Receptors/genetics , ErbB Receptors/physiology , Gene Expression , Molecular Sequence Data , Mutation , Promoter Regions, Genetic , Rats , Signal Transduction , Transforming Growth Factor beta/pharmacology
13.
FEBS Lett ; 491(1-2): 40-4, 2001 Feb 23.
Article in English | MEDLINE | ID: mdl-11226415

ABSTRACT

Transcriptional promoters responsive to low doses of X-irradiation may be useful in developing a new strategy in gene therapy combined with conventional radiotherapy. The retrovirus-mediated gene trap screening identified c-IAP2 as one of genes possessing such promoters. The analysis of the cis-elements responsive to X-irradiation in c-IAP2 promoter revealed that the NF-kappaB binding sites were necessary and sufficient for the X-ray-responsiveness. We constructed the plasmid p4NFB-BAX, which had four tandem repeats of the NF-kappaB binding sites of c-IAP2 promoter (4NFB) and a suicide gene BAX under the control of 4NFB. The human tumor cells transfected with p4NFB-BAX significantly reduced the number of cells that survived 2 Gy irradiation.


Subject(s)
Apoptosis , NF-kappa B/metabolism , Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins/genetics , Adenocarcinoma , Binding Sites , Blotting, Western , Cell Death/radiation effects , Genes, Reporter , Humans , Inhibitor of Apoptosis Proteins , Luciferases/metabolism , NF-kappa B/genetics , Promoter Regions, Genetic , Protein Binding , Proteins/genetics , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Sensitivity and Specificity , Tumor Cells, Cultured , X-Rays , bcl-2-Associated X Protein
14.
Int J Radiat Oncol Biol Phys ; 42(4): 913-6, 1998 Nov 01.
Article in English | MEDLINE | ID: mdl-9845121

ABSTRACT

PURPOSE: Selective gene expression in response to tumor hypoxia may provide new avenues, not only for radiotherapy and chemotherapy, but also for gene therapy. In this study, we have assessed the extent of hypoxia responsiveness of various DNA constructs by the luciferase assay to help design vectors suitable for cancer therapy. MATERIALS AND METHODS: Reporter plasmids were constructed with fragments of the human vascular endothelial growth factor (VEGF) and the erythropoietin (Epo) genes encompassing the putative hypoxia-responsive elements (HRE) and the pGL3 promoter vector. Test plasmids and the control pRL-CMV plasmid were cotransfected into tumor cells by the calcium phosphate method. After 6 h hypoxic treatment, the reporter assay was performed. RESULTS: The construct pGL3/VEGF containing the 385 bp fragment of the 5' flanking region in human VEGF gene showed significant increases in luciferase activity in response to hypoxia. The hypoxic/aerobic ratios were about 3-4, and 8-12 for murine and human tumor cells, respectively. Despite the very high degree of conservation among the HREs of mammalian VEGF genes, murine cells showed lower responsiveness than human cells. We next tested the construct pGL3/Epo containing the 150 bp fragment of the 3' flanking region in the Epo gene. Luciferase activity of pGL3/Epo was increased with hypoxia only in human cell lines. The insertion of 5 copies of the 35-bp fragments derived from the VEGF HREs and 32 bp of the E1b minimal promoter resulted in maximal enhancement of hypoxia responsiveness. CONCLUSIONS: The constructs with VEGF or Epo fragments containing HRE may be useful for inducing specific gene expression in hypoxic cells. Especially, the application of multiple copies of the HREs and an E1b minimal promoter appears to have the advantage of great improvement in hypoxia responsiveness.


Subject(s)
Cell Hypoxia/genetics , Endothelial Growth Factors/genetics , Erythropoietin/genetics , Gene Expression , Genetic Vectors/genetics , Lymphokines/genetics , Transcription Factors , Animals , DNA-Binding Proteins/metabolism , Endothelial Growth Factors/metabolism , Erythropoietin/metabolism , Humans , Hypoxia-Inducible Factor 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Luciferases/metabolism , Lymphokines/metabolism , Mice , Nuclear Proteins/metabolism , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
15.
Transplantation ; 28(3): 196-8, 1979 Sep.
Article in English | MEDLINE | ID: mdl-386583

ABSTRACT

Sera of 58 recipients of renal allografts were studied for the presence of antibodies against cell cultures of human B lymphoid cell lines (B-LCL) and bovine erythrocytes (BRBC). Cytotoxic anti-B-LCL antibodies were found in 13% of the sera from recipients with the grafts and in 67% of the sera obtained after removal of the rejected grafts. Most of these sera also contained BRBC lysins of high titers. Absorption studies showed that the anti-B-LCL antibodies are directed against antigens shared by BRBC and that they can be absorbed with corresponding graft tissues. The specificity of BRBC lysins found in some of the transplantation sera was shown to be similar to that of Hanutziu-Deicher antibodies.


Subject(s)
Antibodies , B-Lymphocytes/immunology , Cross Reactions , Erythrocytes/immunology , Kidney Transplantation , Absorption , Animals , Antibody Specificity , Antigen-Antibody Reactions , Cattle , Cells, Cultured , Guinea Pigs , Humans , Palatine Tonsil/immunology , Transplantation, Homologous
16.
J Biochem ; 111(6): 748-53, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1323564

ABSTRACT

There are at least two types of endothelin receptors, ETA and ETB, present in various tissues. We found that although biotinylated ET-1 could bind to both ETA and ETB receptors, the stability of the formed ligand-receptor complexes was different. When the preformed complexes of receptor (solubilized from canine brain and lung membranes) and biotinylated ET-1 were subjected to avidin agarose column chromatography, most of the ETA activity was recovered in the pass-through fraction and the remainder was recovered in the 0.5 M KSCN eluate as ligand-free forms. On the other hand, the ETB activity bound firmly to the avidin agarose column was eluted with 1.5 M KSCN. The detection of the complex of 125I-ET-1 and its receptor by SDS-PAGE run at a low temperature was only possible with the ETB fractions and the complex of 125I-ET-1 and ETA was unstable during the separation. These results suggest that the conformation of the ligand binding sites of canine ETA and ETB as well as the stability of their ligand-receptor complexes to SDS are significantly different. Similar observations were also obtained for human ETA and ETB receptors.


Subject(s)
Endothelins/metabolism , Receptors, Cell Surface/metabolism , Animals , Binding Sites , Brain/metabolism , Chromatography, Affinity , Dogs , Kinetics , Lung/metabolism , Receptors, Cell Surface/classification , Receptors, Cell Surface/isolation & purification , Receptors, Endothelin
17.
Neuroreport ; 11(5): 1001-5, 2000 Apr 07.
Article in English | MEDLINE | ID: mdl-10790872

ABSTRACT

Using an inducible gene expression system (Tet-ON system), the role of NGFI-A gene during the neuronal differentiation of PCI2 cells was examined. When NGFI-A was transiently over-expressed, no obvious effects on cell proliferation or neurite outgrowth were observed. Interestingly, however, NGFI-A over-expression resulted in significant retardation in NGF-induced neurite outgrowth. Similar suppressive effects were observed also on the v-K-ras-induced neurite outgrowth. These results raise the possibility that NGFI-A protein may play some negative role in NGF signaling.


Subject(s)
DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Developmental/physiology , Immediate-Early Proteins , Nerve Growth Factor/metabolism , Nerve Growth Factor/pharmacology , Neurites/drug effects , Neurites/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Animals , Brain/embryology , Brain/growth & development , Brain/metabolism , Cricetinae , Early Growth Response Protein 1 , Genetic Vectors , Neurites/ultrastructure , PC12 Cells , Rats , Signal Transduction/physiology , Time Factors
18.
Cancer Chemother Pharmacol ; 43(2): 97-105, 1999.
Article in English | MEDLINE | ID: mdl-9923814

ABSTRACT

PURPOSE: The authors have previously reported that trans-bis(n-valerato)(1R,2R-cyclohexanediamine) (oxalato)platinum(IV) (C5-OHP), an oxaliplatin derivative, is an orally active antitumor agent in an intraperitoneal (i.p.) L1210 murine leukemia model. In this study, several oxaliplatin derivatives of the general formula trans-(carboxylato)chloro(1R,2R-cyclohexanediamine)(oxala to)platinum(IV) were synthesized in order to find new derivatives with greater oral activity than C5-OHP in a clinically predictive tumor model. In the formula, the carboxylate and chloride ligands are situated in axial positions. METHOD: Four complexes with the axial carboxylate ligands n-butyrate, n-valerate, n-caproate or n-heptanoate were synthesized and designated C4-OHP-Cl, C5-OHP-Cl, C6-OHP-Cl and C7-OHP-Cl, respectively. The oral antitumor activity of the complexes was evaluated against the murine reticulosarcoma M5076 implanted subcutaneoulsy (s.c.) in to male BDF1 mice. The complexes were administered orally daily for 5 days in two cycles initiated on days 5 and 12 postimplantation. The physicochemical properties were examined by measuring the concentrations of the complexes in test solutions at intervals by HPLC. The pharmacokinetic behaviors of C5-OHP-Cl, C6-OHP-Cl and C5-OHP following a single oral administration were studied in non-tumor-bearing male BDFl mice. RESULTS: Of the complexes synthesized in this study, C5-OHP-Cl, which exhibited high activity in the i.p. L1210 model, was found to be orally active in the s.c. M5076 model while C5-OHP was not. The in vitro reduction of the complexes by ascorbate was much more rapid than that of C5-OHP, while the complexes were more stable than C5-OHP in HCl-acidic and alkaline solutions. Pharmacokinetic study showed that Cmax and AUC0 24h values of plasma total and filterable platinum of C5-OHP-Cl were four to six times greater than those of C5-OHP, indicating that C5-OHP-Cl was absorbed more than C5-OHP. CONCLUSION: C5-OHP-Cl was found to be a superior 1-OHP derivative C5-OHP, exhibiting significant oral antitumor activity in the s.c. M5076 model. The enhanced activity of C5-OHP-Cl was considered to be due in part to increased susceptibility to reduction and increased gastrointestinal absorption. C5-OHP-Cl is a suitable candidate for further study as an oral cancer chemotherapy agent.


Subject(s)
Antineoplastic Agents/pharmacology , Organoplatinum Compounds/pharmacology , Prodrugs/pharmacology , Administration, Oral , Animals , Area Under Curve , Drug Administration Schedule , Female , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred DBA , Organoplatinum Compounds/chemistry , Organoplatinum Compounds/pharmacokinetics , Prodrugs/chemistry , Prodrugs/pharmacokinetics
19.
Anticancer Res ; 20(1A): 357-62, 2000.
Article in English | MEDLINE | ID: mdl-10769680

ABSTRACT

PURPOSE: We examined the anti-tumor effect of 5-S-GAD, a novel potent inhibitor of protein tyrosine kinases, isolated from the flesh fly in order to investigate the potential use of this compound as an anti-tumor agent. METHODS: In vitro growth inhibition was evaluated using the alamarBlue assay kit. In vivo anti-tumor activity was evaluated by i.p. treatment of 5-S-GAD against xenografted melanoma (LOX-IMV1) and breast carcinoma (MDA-MB-435S) in nude mice. RESULTS: Of 38 human cancer cell lines examined, this compound showed significant cytotoxicity toward two estrogen-negative breast carcinomas (MDA-MB-231 and MDA-MB-435S) and one malignant melanoma (LOX-IMV1) in vitro, indicating that it exhibits selective cytotoxicity to certain tumor cell lines. In accordance with its in vitro anti-tumor effect, 5-S-GAD was shown to significantly repress the growth of sensitive tumor cells in nude mice. CONCLUSION: These results indicate that 5-S-GAD is potentially useful to treat certain human cancer.


Subject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms/pathology , Dihydroxyphenylalanine/analogs & derivatives , Diptera/chemistry , Glutathione/analogs & derivatives , Mammary Neoplasms, Experimental/drug therapy , Melanoma, Experimental/drug therapy , Melanoma/pathology , Animals , Antineoplastic Agents/pharmacology , Benzoquinones , Dihydroxyphenylalanine/pharmacology , Dihydroxyphenylalanine/therapeutic use , Drug Screening Assays, Antitumor , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Female , Glutathione/pharmacology , Glutathione/therapeutic use , Humans , Lactams, Macrocyclic , Mice , Mice, Nude , Molecular Structure , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Transplantation , Protein-Tyrosine Kinases/antagonists & inhibitors , Quinones/pharmacology , Rifabutin/analogs & derivatives , Transplantation, Heterologous , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/transplantation
20.
Biomed Pharmacother ; 51(10): 474-9, 1997.
Article in English | MEDLINE | ID: mdl-9863509

ABSTRACT

We reviewed the records of 12 patients with HIV infection (one stage I, three stage II, two stage III, six stage IV) who received 15 surgical procedures under general or lumbar/epidural anesthesia. We discussed surgical indications, their poor wound healing and precautions for preventing the risk of transmission of HIV to health care workers. Six emergency and nine elective operations were performed. Postoperative complications developed after three emergency and three elective operations. Ten patients showed delay of wound healing which was not directly correlated with the CD4+ cell count. No operative deaths occurred. In any stage of HIV infection, not only palliative but also curative operations can be performed as long as HIV infection, opportunistic infections and HIV-related neoplasms can be controlled. Late stage wound healing is poor, but the wound will heal without keloid formation, although it takes two to three times longer than usual. For operating on patients with HIV infection precautions for preventing needle sticks, sharp injuries and blood exposure should be learned and used by health care workers. As a result, surgical staff members will be able to perform operations safely on HIV-infected patients to improve both quality of life and the prognosis of their disease.


Subject(s)
HIV Infections/complications , Surgical Procedures, Operative , Adult , Anesthesia, Epidural , Anesthesia, Spinal , HIV Infections/prevention & control , HIV Infections/transmission , Humans , Japan , Middle Aged , Postoperative Complications , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL